BioSpace News Archive

Imvax, Inc. , a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies, announced two poster presentations.

SQZ Biotechnologies Presents Cell Squeeze ® Manufacturing Platform, Linked Antigen mRNA Preclinical Research, and COMMANDER-001 Phase 1/2 Clinical Trial in Progress Poster at Society for Immunotherapy of Cancer Annual Meeting.

PicnicHealth, a patient-centered health technology company, today announced an engagement with Bristol Myers Squibb to leverage patient-centered, real-world evidence generation to complement Bristol Myers Squibb’s DISCOVER-HCM Registry, a 1,500-patient registry of consented symptomatic obstructive hypertrophic cardiomyopathy (oHCM) patients receiving CAMZYOS (mavacamten) or other treatment.

Scopus BioPharma Inc. and its pure-play immuno-oncology subsidiary, Duet BioTherapeutics, today announced that key scientific data will be will be presented at the 37th Annual Meeting and Exposition of the Society for Immunotherapy of Cancer (“SITC”). SITC is being held from November 8-12, 2022.

Bicycle Therapeutics plc today announced that preclinical data for BT7480 will be presented in five poster presentations at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting, being held in Boston, M.A. and virtually on November 8-12, 2022.

Venture Exchange (“TSXV”) has approved the Company’s application to list its common shares (the “Shares”) on the TSXV. The Shares will commence trading on the TSXV under the ticker symbol “MGRO” at the opening of the Market on November 11, 2022.

Aulos Bioscience today presented early data from its Phase 1/2 study of AU-007.

ScreenPro Security Inc. (CSE: SCRN) (OTCQB: SCRSF) (“ScreenPro” or the “Company”) is pleased to announce a non-brokered private placement financing of up to 20 million units of the Company (“Units”) at a price of $0.05 per Unit (the “Private Placement”).

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced a booster dose of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine (COMIRNATY ® Original/Omicron BA.4/BA.5 5/5-µg) has been recommended for marketing authorization by the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) for children 5 through 11 years of age.

Centinel Spine®, LLC, (“the Company”) a leading global medical device company addressing cervical and lumbar spinal disease through anterior surgical access, today announced the first implantation of its prodisc® C SK Cervical Total Disc Replacement (TDR) product.